LONDON, Nov. 28, 2017 /PRNewswire/ — Download the full report: https://www.reportbuyer.com/product/5214368
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 184.108.40.206) – Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 220.127.116.11) pipeline Target constitutes close to 32 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 4, 1, 12 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Adenocarcinoma, Bladder Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, B-Cell Non-Hodgkin Lymphoma, Cervical Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Psoriasis, Renal Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Type 1 Diabetes (Juvenile Diabetes).
The latest report Indoleamine 2,3 Dioxygenase 1 – Pipeline Review, H2 2017, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific